Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas
Executive Summary
Last week’s US House and Senate hearings on drug pricing underscore how quickly the negative attention has turned to industry. With more public discussions planned – including potential testimony from pharma execs – here’s what can be expected in the months ahead.
You may also be interested in...
Democratic Drug Pricing Push: Starting And Ending With Insulin?
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.
Building A Wall? The Plan To End “March In” Threat To US Drug Patents
Calls to exercise “march in” rights on federal patents licensed to pharmaceutical companies are a recurring theme in the US drug pricing debate. Now the Department of Commerce is proposing to make those threats even emptier than they already are.
Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019
Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.